Dear Study Participants/Study Volunteers:
The safety of our clinical trial volunteers and employees is M3 Wake Research top priority. We have been actively monitoring the Coronavirus (COVID-19) spread, and have added supplemental measures based on information from the Centers for Disease Control and Prevention (CDC) and World Health Organization (WHO). In order to maintain a safe environment for our volunteers, employees, and partners, our company is taking the following steps:
- Minimizing exposure at our research sites/facilities. All trial volunteers, employees, vendors, and sponsors will have their temperature checked prior to entry to our facility. Volunteers will go through an additional phone and in-person questioning before conducting a study visit. We have also limited all non-essential access to all our facilities. Our intent is to minimize potential exposure while ensuring clinical trial continuity to the maximum extent possible.
- Virtual appointments. When possible appointments can be done virtually so the patient or participant does not have to come into the office.
- Enhanced cleaning protocols. We have increased the frequency of disinfecting and cleaning service at our research sites and have provided additional hand sanitizer stations.
- Education and communication. We are in close communication with our on-trial and potential volunteers and are providing them with information about how they can stay safe and healthy during this time. We are also preparing them for what to expect when they visit our facilities, given our enhanced screening and safety measures. Our employees receive frequent updates on the COVID-19 situation, including precautionary tips and best practices to stay safe.
Our priority remains to keep our volunteers and employees safe and well-informed while doing what we can to help minimize the potential spread of the coronavirus. We will continue to dedicate significant resources and efforts to mitigate the risks while still ensuring business continuity to the greatest extent possible.